Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast
OSLO, Norway, Oct. 17, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be announced nearer the time).
During this presentation, the Company will present updated clinical results from the LYMRIT 37-01 trial with Betalutin® in relapsed/refractory indolent non-Hodgkin's lymphoma patients. These results will be published on 1 November in an abstract* that will be presented in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018).
As a consequence of the change in date of the third quarter 2018 results presentation, the Company will enter its two-week 'quiet period' starting on the 23 October 2018.
In addition, the Company has decided it will not continue hosting separate presentations of the results in Norwegian.
Title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin's lymphoma (NHL) - Analysis with 6-month follow-up
Authors: A. Kolstad, et al.
The abstract will be published on 1 November 2018 at 09:00am Eastern time at http://www.hematology.org/Annual-Meeting/
For further information, please contact:
VP Investor Relations and Corporate Communications
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector
Company Codes: Bloomberg:NANO@NO, Dusseldorf:8NN, ISIN:NO0010597883, LSE:0R6Y, Oslo:NANO, RICS:NANO.OL, Stockholm:NANOO, Frankfurt:8NN, Stuttgart:8NN